Litcius/Paper detail

DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity

Mette Saksø, Kenneth Jensen, Maria Andersen, Christian Rønn Hansen, Jesper Grau Eriksen, Jens Overgaard

2020Radiotherapy and Oncology26 citationsDOI

Topics & Concepts

ConcomitantCisplatinMedicineOncologyInternal medicineRadiation therapyBasal cellChemotherapyHead and Neck Cancer StudiesEsophageal Cancer Research and TreatmentOral health in cancer treatment
DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity | Litcius